### PHASE 1
**2017 – 2018**
*Initiation: Literature Review*

- Conduct global scientific scan of patient reported outcomes literature.
- Develop database of patient organizations.

### PHASE 2 & 3
**2019 – 2021**
*Understanding Impacts & Patient Prioritization of Impacts*

- Identify issues associated with the patients’ diseases.
- Develop new methodology (called GRIP) to collect impact areas.
- Gather primary data from patients via focus groups and interviews.
- Conduct Delphi process to validate and affirm the data.

### PHASE 4
**2021 – 2022**
*Testing & Finalizing PRIDD*

- Pilot-test PRIDD with patients and leverage patient insights to make refinements.
- Conduct psychometric testing to make final refinements and quality check PRIDD.

### PHASE 5
**2022 - 2023**
*Translate, Cultural Adaptation, Launch PRIDD*

- Launch PRIDD globally - patient impact measurement tool.
- Report scale development and peer review processes.
- Translate PRIDD into different languages.
- Create disease-specific versions of PRIDD.

### PHASE 6
**2023+**
*Data analysis & Application*

- Collect global impact data.
- Analyze & share GRIDD data.
- Publish articles and reports.
- Educate stakeholders and public.
- Deliver advocacy campaign.
- Offer patient organizations’ leader training and support.

### OBJECTIVES
- Conduct global scientific scan of patient reported outcomes literature.
- Develop database of patient organizations.
- Identify issues associated with the patients’ diseases.
- Develop new methodology (called GRIP) to collect impact areas.
- Gather primary data from patients via focus groups and interviews.
- Conduct Delphi process to validate and affirm the data.
- Pilot-test PRIDD with patients and leverage patient insights to make refinements.
- Conduct psychometric testing to make final refinements and quality check PRIDD.
- Launch PRIDD globally - patient impact measurement tool.
- Report scale development and peer review processes.
- Translate PRIDD into different languages.
- Create disease-specific versions of PRIDD.
- Collect global impact data.
- Analyze & share GRIDD data.
- Publish articles and reports.
- Educate stakeholders and public.
- Deliver advocacy campaign.
- Offer patient organizations’ leader training and support.

### OUTCOMES
- 12,927 scientific articles reviewed.
- 36 dermatology-specific patient-reported measures identified.
- No measure met Cosmin Category A criteria (i.e. none met gold standard).
- Journal article published in Acta Dermato-Venereologica and results presented at international conferences.
- Patient impact dataset created.
- First draft of new patient impact measurement tool (called PRIDD).
- Poster sessions and paper(s) published on GRIDD research.
- Journal article on the impact of dermatological conditions on patients’ lives submitted.
- Pilot and test PRIDD – gold standard patient impact measurement tool.
- Final version of PRIDD patient impact measurement tool developed and launched.
- Poster sessions and paper(s) published on GRIDD research.
- Scientifically sound cross-cultural and disease-specific versions of PRIDD.
- Poster sessions and paper(s) published on GRIDD research.
- Scientifically sound cross-cultural and disease-specific versions of PRIDD.
- Poster sessions and paper(s) published on GRIDD research.

### BENEFITS of GRIDD

#### PATIENT ORGANIZATIONS
- Access to data from PRIDD – the world’s first dermatology patient impact measurement tool.
- Evidence to support their missions and fundraising.
- Training, resources to support their work and in turn their patients.
- Patient’s voice integrated in future decision-making.

#### DATA & EVIDENCE
- Gap in patient-driven research now filled that will:
  - Support publications and reports.
  - Advance research employing the GRIDD patient impact measurement tool.
  - Inform better public health policy.
  - Further center the patient perspective in research (including clinical trials).

#### ADVOCACY & COMMUNICATIONS
- Provide support for GlobalSkin member campaigns to advance their priorities.
- Educate via a global campaign adapted for each country.
- Facilitate informed advocacy at local, regional and country levels to improve diagnosis, care and access to treatments.

#### GLOBAL DERMATOLOGY
- Advocate via a global campaign to advance dermatology.
- Build a larger global network of dermatology stakeholders.
- Elevate dermatology as a global health care priority (e.g. WHO, UN, Disability-Adjusted Life Years).